Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption

Y Shitara, K Maeda, K Ikejiri, K Yoshida… - … & drug disposition, 2013 - Wiley Online Library
Organic anion transporting polypeptide (OATP) family transporters accept a number of drugs
and are increasingly being recognized as important factors in governing drug and …

A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists

MC Michel, C Foster, HR Brunner, L Liu - Pharmacological reviews, 2013 - ASPET
Angiotensin II type 1 receptor antagonists (ARBs) have become an important drug class in
the treatment of hypertension and heart failure and the protection from diabetic nephropathy …

Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension

ZH Israili - Journal of human hypertension, 2000 - nature.com
Angiotensin II receptor blockers (ARBs) represent a new class of effective and well tolerated
orally active antihypertensive agents. Recent clinical trials have shown the added benefits of …

Efficiency of ozonation and O3/H2O2 as enhanced wastewater treatment processes for micropollutant abatement and disinfection with minimized byproduct formation

W Lee, S Choi, H Kim, W Lee, M Lee, H Son… - Journal of Hazardous …, 2023 - Elsevier
Ozonation, a viable option for improving wastewater effluent quality, requires process
optimization to ensure the organic micropollutants (OMPs) elimination and disinfection …

Clinical pharmacokinetics of losartan

DA Sica, TWB Gehr, S Ghosh - Clinical pharmacokinetics, 2005 - Springer
Losartan is the first orally available angiotensin-receptor antagonist without agonist
properties. Following oral administration, losartan is rapidly absorbed, reaching maximum …

Valsartan: a review of its pharmacology and therapeutic use in essential hypertension

A Markham, KL Goa - Drugs, 1997 - Springer
Synopsis Valsartan competitively and selectively inhibits the actions of angiotensin II at the
AT 1 receptor subtype which is responsible for most of the known effects of angiotensin II. In …

A review on telmisartan: a novel, long‐acting angiotensin II‐receptor antagonist

W Wienen, M Entzeroth, JCA van Meel… - Cardiovascular drug …, 2000 - Wiley Online Library
Telmisartan is a potent, long‐lasting, nonpeptide antagonist of the angiotensin II type‐1
(AT1) receptor that is indicated for the treatment of essential hypertension. It selectively and …

Effects of liver disease on pharmacokinetics: an update

V Rodighiero - Clinical pharmacokinetics, 1999 - Springer
Liver disease can modify the kinetics of drugs biotransformed by the liver. This review
updates recent developments in this field, with particular emphasis on cytochrome P450 …

Absorption, Metabolism, and Excretion of Intravenously and Orally Administered [14C]Telmisartan in Healthy Volunteers

J Stangier, J Schmid, D Türck, H Switek… - The Journal of …, 2000 - Wiley Online Library
The study was conducted in healthy male volunteers to evaluate the absorption, metabolic
pattern, and mode of elimination of telmisartan, a nonpeptide angiotensin II receptor …

Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans

W Yamashiro, K Maeda, M Hirouchi, Y Adachi… - Drug metabolism and …, 2006 - ASPET
Valsartan is a highly selective angiotensin II AT1-receptor antagonist for the treatment of
hypertension. Valsartan is mainly excreted into the bile in unchanged form. Because …